Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03362489
Other study ID # 2017-A00862-51
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 10, 2018
Est. completion date March 14, 2024

Study information

Verified date June 2024
Source University Hospital, Angers
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficiency of conversion to IUI and IVF in patients with a poor ovarian response to stimulation


Description:

In 5 to 10% of in vitro fertilization (IVF) cycles, a poor response to ovarian stimulation (defined as less than 4 mature follicles) is noted, even though high doses of exogenous gonadotropins are used. To date, there is no consensus on the ideal management strategy in poor responders. There are three therapeutic options available nowadays: 1. Oocyte retrieval is performed and the IVF cycle continued, despite the low number of mature follicles. 2. Conversion of the IVF cycle to an intrauterine insemination (IUI), on the condition of having at least one patent fallopian tube and good semen parameters. 3. Cancelation of the IVF cycle. In everyday practice, it is difficult for the physician to cancel the IVF cycle in the presence of 2, 3 or 4 mature follicles, especially following a lengthy stimulation. If live birth rates were comparable between IUI and IVF, conversion to IUI would be the better option for poor responders, since it would avoid an invasive procedure (oocyte retrieval) and the associated risk of complications, and is associated with at a lower cost. To our knowledge, no prospective randomized controlled trial comparing IVF to conversion to IUI in poor responders has been published to date. The studies published so far have been retrospective and observational, and had several methodological flaws. Therefore, we aimed to analyze whether conversion of IVF cycles to IUI in poor responders would result in the same live birth rates as oocyte retrievals followed by embryo transfers.


Recruitment information / eligibility

Status Completed
Enrollment 462
Est. completion date March 14, 2024
Est. primary completion date November 25, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 43 Years
Eligibility Inclusion Criteria: - Patients who accepted being included and signed the consent forms. - Age =18 years et <43 years. - IVF cycle with and without Intra Cytoplasmic Sperm Injection (ICSI): - "Conventional" Agonist (long and short) or antagonist protocol, using urinary or recombinant gonadotropins. - Having only 2, 3 or 4 mature follicles (=14 mm) on ovulation trigger day. Exclusion Criteria: - Confirmed bilateral tubal occlusion - Non-French speaking patients - Partners with severe oligoasthenoteratospermia (OATS) (<5 millions motile spermatozoa in the ejaculate) - Suboptimal stimulation protocols: - Protocols = 150 IU of daily gonadotropins - Mild stimulation protocols - Natural and modified natural cycle protocols - Women under legal guardianship - Women with no health or social security coverage - Women participating in other interventional trials

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
IVF / IVF-ICSI
In the "IVF" arm, oocyte retrieval is performed 36 hours after the HCG injection, in the operating room, under transvaginal ultrasound guidance, under local or general anesthesia. The procedure lasts about 20 minutes and the patients are discharged on the same day. The oocytes retrieved from the follicles are transported immediately to the lab for fertilization with the partner's sperm. Fertilization is done either via conventional IVF, or via ICSI, depending on the indication. Embryos are later transferred into the uterus on day 3 or day 5, under ultrasound guidance, in the outpatient department.
IUI
In the "conversion to IUI" arm, IUI is performed 24 to 36 hours after ovulation trigger. The partner provides the sperm on site on the morning of the insemination, which is performed in the outpatient department.

Locations

Country Name City State
France Victor Pauchet Clinic Amiens
France UH Angers Angers
France UH Besançon Besançon
France Jean Verdier Hospital, APHP Bondy
France Polyclinique Jean Villar Bruges
France UH Caen Caen
France Clinique Léonard de Vinci Chambray-lès-Tours
France Cholet Hospital Cholet
France Antoine Béclère Hospital AP-HP Clamart
France Sud Francilien Hospital Corbeil-Essonnes
France IHC Créteil Créteil
France UH Grenoble Grenoble
France Tertre Rouge Clinic Le Mans
France UH Lille Lille
France Lorient Hospital Lorient
France UH La conception AP-HM Marseille
France Clinique Jules Verne Nantes
France UH Nantes Nantes
France Clinique Pierre Cherest Neuilly-sur-Seine
France UH Nîmes Nîmes
France Hospital of Orléans Orléans
France Cochin Hospital, APHP Paris
France Poissy Saint Germain en Laye Hospital Poissy
France UH Potiers Potiers
France Clinique Mutualiste de la Sagesse Rennes
France UH Rennes Rennes
France UH Rouen Rouen
France Polyclinique de L'Atlantique Saint-Herblain
France UH Strasbourg Strasbourg
France UH Toulouse Toulouse
France UHR Tours Tours
Guadeloupe UH Pointe-à-Pitre Pointe-à-Pitre Guadeloupe/France

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Angers

Countries where clinical trial is conducted

France,  Guadeloupe, 

Outcome

Type Measure Description Time frame Safety issue
Primary The main criterion is the live birth rate Defined as the birth of a living infant after 22 weeks gestational age (GA), or weighing = 500 g. 12 months
Secondary Biochemical pregnancy rate Defined as serum HCG levels >10 IU/L, 14 days after the IUI or the embryo transfer, followed by a rapid decrease until being undetectable. 5 Weeks
Secondary Clinical pregnancy rate Defined as fetal cardiac activity at 6-7 weeks GA 6-7 Weeks
Secondary Spontaneous pregnancy loss (PL) rate Including early and late pregnancy losses 12 Weeks
Secondary Multiple pregnancy rate Defined as more than two embryos visualized on ultrasound at 7 weeks GA. 7-8 Weeks
Secondary Term at delivery Term at delivery in Gestational age (GA) 12 Months
Secondary Neonatal complications Neonatal complications 12 Months
Secondary Neonatal survival Neonatal survival 12 Months
Secondary All outcome measure will be further analyzed according to the number of follicles on trigger day (2, 3 or 4) and patients' age (<40 years vs. =40 years) Assess the impact of conversion to IUI, compared to IVF, on overall outcomes in in women with a poor ovarian response to stimulation, according to the number of follicles on trigger day (2, 3 or 4) and patients' age (<40 years vs. =40 years) 12 Months
Secondary All outcome measures will be further analyzed in the subgroup of women considered poor responders according to the Bologna criteria Assess the clinical efficiency of conversion to IUI, compared to IVF, in women considered "poor ovarian responders" according to the Bologna criteria 12 Months
Secondary The rate of IVF cycles with empty follicle syndrome and no embryo transfers. Analyze the rate of IVF cycles with empty follicle syndrome and no embryo transfers 1 Week
Secondary Cumulative clinical pregnancy and live birth rates in the IVF group, thus taking into account fresh and frozen embryos transferred in subsequent cycles Assess the impact of conversion to IUI, compared to IVF, on the cumulative clinical pregnancy and live birth rates - taking into account frozen embryo transfers in IVF - in women with a poor ovarian response to stimulation 12 Months
Secondary Cost-efficiency analysis at 12 months Compare the cost-efficiency of both strategies at 12 months 12 Months
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A